The Gleason score is one of a number of factors used in staging patients diagnosed with prostate cancer and in determining the treatment path such patients will ultimately follow. However, discrepancies in the Gleason scores obtained through biopsy compared with the final pathological staging of specimens following radical prostatectomy are not uncommon.
Incorrect Gleason scoring can potentially influence treatment decisions and therefore, it is imperative that research is undertaken to elucidate factors that may be able to predict whether a patient's Gleason score might need to be reconsidered. A literature review was undertaken in late 2014 to highlight some of these factors that require further investigation.
Urologia internationalis. 2015 Aug 29 [Epub ahead of print]
David Rhys Alchin, Declan Murphy, Nathan Lawrentschuk
University of Melbourne, Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Vict. , Australia.